Black Diamond Therapeutics, Inc.

93 articles about Black Diamond Therapeutics, Inc.

• Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update

  3/24/2020

  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results for the fourth quarter and full year ended December 31, 2019, while providing a corporate update.

• Black Diamond Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

  2/24/2020

  CAMBRIDGE, Mass. and NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the Cowen and Company 40 th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on

• Black Diamond Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

  2/3/2020

  Black Diamond Therapeutics, Inc. announced the closing of its initial public offering of 12,174,263 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share.

• Versant Ventures Announces Successful IPO by Black Diamond Therapeutics

  1/30/2020

  First company launched by Versant’s Ridgeline Discovery Engine

• Black Diamond Therapeutics Announces Pricing of Initial Public Offering at $19.00 per share

  1/30/2020

  Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share.

• Black Diamond Therapeutics Closes $85 Million Series C Financing

  12/5/2019

  Company also announces CRISPR Therapeutics CEO Samarth Kulkarni, Ph.D., Joins its Board of Directors

• Black Diamond Therapeutics to Present Preclinical Data on its Lead Product Candidate BDTX-189 at the European Society for Medical Oncology 2019

  9/26/2019

  Black Diamond Therapeutics, Inc. announced that preclinical data defining the molecular mechanism for oncogenic activation of families of epidermal growth factor receptor allosteric mutations and showing activity of the Company's lead product candidate BDTX-189 will be presented at the European Society for Medical Oncology Congress 2019, taking place from September 27 to October 1, 2019 in Barcelona, Spain.

• Black Diamond Therapeutics Names Christopher Roberts, Ph.D., as Chief Scientific Officer

  9/19/2019

  Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Christopher D. Roberts, Ph.D., as Chief Scientific Officer.

• Black Diamond Therapeutics Appoints Thomas Leggett as Chief Financial Officer

  9/12/2019

  Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer (CFO).

• Black Diamond Therapeutics Appoints Industry Veteran as Chief Operating Officer and General Counsel

  5/29/2019

  Team also strengthened with key hires in preclinical and clinical development, clinical operations, and finance to drive company's lead program into the clinic in 2020 and advance its pipeline and MAP platform

• Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting

  3/29/2019

  Black Diamond Therapeutics, Inc. announced that data from its first-in-class program targeting a group of epidermal growth factor receptor allosteric mutants that drive glioblastoma multiforme will be presented at the American Association for Cancer Research Annual Meeting 2019.

• Black Diamond Therapeutics Closes $85 Million Series B Financing

  1/10/2019

  Next-wave precision oncology company poised to advance multiple products into clinical development

• Versant Ventures Launches Black Diamond Therapeutics

  12/11/2018

  Next-wave precision oncology company emerges from Versant’s Ridgeline Discovery Engine